{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1660",
  "slug": "cancers-hiding-places-three-ways-in",
  "edition": "2026-11-17T00",
  "url": "https://hangingcontext.com/stories/2026-11-17/cancers-hiding-places-three-ways-in/",
  "newsroom": "research-science",
  "beat": null,
  "newsroom_title": "Research & Science",
  "angle": "Three preprints expose how glioblastoma, melanoma and regulatory T cells hide, and where each can be hit.",
  "headline": "Three cancers, three hiding places — and three ways in",
  "dek": "A glioblastoma protein that buffers oxidative stress, a melanoma regulator that changes roles with the tumor's mutation, and regulatory T cells that turn senescent without losing their grip. Three preprints, one lesson: cancers protect themselves in specific, targetable ways.",
  "published_at": "2026-11-17T00:58:26Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 3 Manifests",
    "newsroom": "Research & Science"
  },
  "source_count": 3,
  "publishers": [
    "biorxiv-cancer-immunology-translation"
  ],
  "sources": [
    "biorxiv-cancer-immunology-translation"
  ],
  "distinct_source_count": 1,
  "key_facts": [
    {
      "text": "In a bioRxiv preprint, researchers identify SLC25A39 as a hypoxia-inducible mitochondrial carrier that buffers oxidative stress in glioblastoma; losing it makes the cells highly sensitive to the Bcl-2/Bcl-xL inhibitor navitoclax.",
      "cites": [
        {
          "claim_ids": [],
          "manifest_id": "1794858106200498930"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a bioRxiv preprint, loss of the signaling hub LATS1 drives different effects by melanoma subtype: an immune-evasive profile in BRAF-mutant tumors and disrupted DNA damage repair in NRAS-mutant tumors.",
      "cites": [
        {
          "claim_ids": [],
          "manifest_id": "1794839025705334125"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a bioRxiv preprint, tumor-infiltrating regulatory T cells acquire a senescence-like state marked by p16, p21 and SASP while keeping their immunosuppressive activity, opening a possible window to target them selectively.",
      "cites": [
        {
          "claim_ids": [],
          "manifest_id": "1794839025706334127"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "The hiding places",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794858106200498930"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794839025705334125"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794839025706334127"
            }
          ],
          "markdown": "Three bioRxiv preprints describe three different ways cancers protect themselves, and in each case the protection itself is the opening. A glioblastoma protein buffers the oxidative stress that would otherwise kill the tumor. A melanoma signaling hub changes what it does depending on which mutation drives the tumor. And the regulatory T cells inside a tumor take on a senescent appearance while keeping their ability to suppress the immune response. None of these is a new drug. Each is a defined weakness a drug program can aim at."
        },
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794858106200498930"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794839025705334125"
            }
          ],
          "markdown": "What connects them is specificity. The findings do not say that a target works in all cancers or even in all patients with one cancer. They say where the vulnerability sits, in which subtype, and what combination it points toward. For a drug developer, that is the useful kind of result: it narrows the next experiment instead of widening it."
        }
      ]
    },
    {
      "heading": "Glioblastoma's oxygen buffer",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794858106200498930"
            }
          ],
          "markdown": "The glioblastoma paper centers on SLC25A39, which the researchers identify as a hypoxia-inducible mitochondrial carrier that buffers oxidative stress in the tumor. Glioblastomas grow in low-oxygen conditions, and the protein appears to be part of how they survive that environment. When the protein is lost, the cells undergo metabolic reprogramming and become highly sensitive to navitoclax, an inhibitor of the survival proteins Bcl-2 and Bcl-xL."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794858376264501759"
              ],
              "manifest_id": "1794858106200498930"
            }
          ],
          "markdown": "The practical consequence the authors draw is a combination rationale built on one finding: losing SLC25A39 makes glioblastoma cells highly sensitive to navitoclax. That is still a preprint claim, not a clinical result, but it is a testable one. It tells a trial designer what to measure — whether the cells that have lost the protein are the ones navitoclax kills — which is the decision a preclinical finding is supposed to enable."
        }
      ]
    },
    {
      "heading": "Melanoma's split personality",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794839025705334125"
            }
          ],
          "markdown": "The melanoma paper is a warning against treating a target as one thing. LATS1 acts as a signaling hub, and its loss drives distinct outcomes depending on the tumor's driver mutation. In BRAF-mutant melanoma, LATS1 deficiency correlates with an immune-evasive profile, meaning the tumor becomes better at hiding from the immune system. In NRAS-mutant melanoma, the same loss disrupts DNA damage repair pathways instead. The protein is the same. The consequence is not."
        },
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794839025705334125"
            }
          ],
          "markdown": "That split is the point for anyone building a melanoma program. A drug aimed at LATS1 biology would need a different rationale, and probably a different combination partner, in BRAF-mutant disease than in NRAS-mutant disease. The authors present LATS1 as a potential therapeutic target for melanoma subtypes that currently lack effective targeted options, which is a real gap — but the work says the target has to be approached subtype by subtype, not as a single program."
        }
      ]
    },
    {
      "heading": "The T cells that will not quit",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794839025706334127"
            }
          ],
          "markdown": "The third paper looks at the immune cells inside the tumor rather than the tumor itself. Tumor-infiltrating regulatory T cells, the cells that suppress immune attack, acquire a senescence-like state marked by the proteins p16 and p21 and by SASP, the secretory program associated with senescent cells. The surprise is what does not happen: unlike typical senescent cells, which lose functional fitness, these regulatory T cells keep their immunosuppressive activity."
        },
        {
          "cites": [
            {
              "claim_ids": [],
              "manifest_id": "1794839025706334127"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794858106200498930"
            },
            {
              "claim_ids": [],
              "manifest_id": "1794839025705334125"
            }
          ],
          "markdown": "That combination — senescent markers with working suppression — is what creates the opening. If the senescence-like state is distinct to these tumor-infiltrating cells, it may be possible to target them selectively without wiping out regulatory T cells elsewhere in the body, where they keep the immune system from attacking healthy tissue. The authors describe this as a potential therapeutic window. Like the other two papers, it is a preclinical finding that names the next experiment: test whether removing these cells, and only these cells, lets an immune response through."
        }
      ]
    }
  ],
  "unresolved": [
    "All three papers are preprints and have not been peer-reviewed.",
    "The navitoclax sensitivity of SLC25A39-deficient glioblastoma cells has not been tested in patients.",
    "Whether the senescence-like state of tumor-infiltrating regulatory T cells can be targeted without harming regulatory T cells elsewhere is not shown."
  ],
  "decision_card": {
    "not_for": [
      "Treatment decisions for any individual patient",
      "Claims about drugs already proven in the clinic"
    ],
    "useful_for": [
      "Drug developers choosing combination targets in brain and skin cancer",
      "Teams weighing which immune-suppressive cells to target first"
    ],
    "compare_against": [
      "Single-target cancer drug programs that ignore the tumor's protective context",
      "Broad immune activation without a defined cellular target"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-17T00"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794858106200498930",
    "1794839025705334125",
    "1794839025706334127"
  ],
  "manifests": [
    {
      "title": "SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.12.765851v1.full",
      "manifest_id": "1794858106200498930",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-16"
    },
    {
      "title": "Integrative analysis identifies LATS1 as a context-specific regulator of melanoma progression and immune response",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.12.766289v1.full",
      "manifest_id": "1794839025705334125",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-16"
    },
    {
      "title": "A Senescence-Like State is associated with the Immunosuppressive Phenotype of Tumor-Infiltrating Regulatory T Cells",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.12.766305v1.full",
      "manifest_id": "1794839025706334127",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-16"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794858106200498930",
      "1794839025705334125",
      "1794839025706334127"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. Existing 72 Hour Agent Demo keys keep their issued limits. New keys require email OTP verification. An existing demo key lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794858106200498930",
      "all": "for id in 1794858106200498930 1794839025705334125 1794839025706334127; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-17/cancers-hiding-places-three-ways-in/",
    "json": "https://hangingcontext.com/stories/2026-11-17/cancers-hiding-places-three-ways-in/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-17/cancers-hiding-places-three-ways-in/index.md",
    "newsroom": "https://hangingcontext.com/n/research-science/",
    "edition": "https://hangingcontext.com/editions/2026-11-17T00/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/molecular-prediction-hits-its-limits/",
      "headline": "The molecule models work — until the change is large",
      "slug": "molecular-prediction-hits-its-limits"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-21/chemistry-aimed-outside-the-lab/",
      "headline": "Chemistry's new papers are pointed at the world outside the lab",
      "slug": "chemistry-aimed-outside-the-lab"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-20/battery-fade-is-not-always-damage/",
      "headline": "Battery fade is not always damage — sometimes the chemistry just needs a stir",
      "slug": "battery-fade-is-not-always-damage"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-20/chemistry-checks-its-own-tools/",
      "headline": "Before you trust the model, check the measurement",
      "slug": "chemistry-checks-its-own-tools"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Claims with a source link",
    "text": "A Manifest holds a Signal of structured claims and a Brief, plus the source it came from. Your agent can check a sentence against it.",
    "cta": {
      "label": "Read the guide",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-17/cancers-hiding-places-three-ways-in/"
  }
}
